Fresenius Medical Care Australia and New Zealand Revenue and Competitors

Milsons Point, Australia

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Fresenius Medical Care Australia and New Zealand's estimated annual revenue is currently $14.3M per year.(i)
  • Fresenius Medical Care Australia and New Zealand's estimated revenue per employee is $251,000

Employee Data

  • Fresenius Medical Care Australia and New Zealand has 57 Employees.(i)
  • Fresenius Medical Care Australia and New Zealand grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$182.7M52022%$124.5MN/A
#2
$33.9M135-2%N/AN/A
#3
$5.4M43-23%$20.8MN/A
#4
$14.3M5710%N/AN/A
#5
$33.4M133-13%$5MN/A
#6
$19.3M778%N/AN/A
#7
$28.4M113-3%N/AN/A
#8
$257.3M10250%N/AN/A
#9
$22.6M90-2%N/AN/A
#10
$35.9M1438%N/AN/A
Add Company

What Is Fresenius Medical Care Australia and New Zealand?

With more than three decades of experience in dialysis and innovative research, Fresenius Medical Care - THE RENAL COMPANY - is the world's leading provider of products and services for people undergoing dialysis. As a vertically integrated company we are involved in all aspects of finding solutions for chronic kidney disease, from research and development of new therapies, to manufacturing our dialysis products, right through to offering comprehensive therapy options within our clinics. Because we are familiar with all these areas of kidney care, we are able to offer different therapies to suit to the needs of each individual patient. In Australia, Fresenius Medical Care has been providing life-saving therapies to renal patients for almost two decades. Our many years of experience in providing life-saving therapies for renal patients means we intimately understand the impact chronic kidney failure has on people's lives. We care for each patient's individual situation, whether they want to stay in their familiar surroundings at home or receive dialysis in one of our clinics across the country. We are the largest private provider of dialysis care in Australia. With a team of around 500 employees, we care for more than 2,300 patients across our clinic network and home dialysis programs. We offer high quality care with state-of-the-art haemodialysis treatment in our clinics or at home, as well as peritoneal dialysis therapies. Fresenius Medical Care - THE RENAL COMPANY Sharing A Lifelong Commitment to patients and healthcare professionals through our core values of quality, commitment and a customer-centric belief.

keywords:N/A

N/A

Total Funding

57

Number of Employees

$14.3M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fresenius Medical Care Australia and New Zealand News

2022-04-20 - Global Plasmapheresis Machines Market 2022 Research ...

Fresenius Medical Care; Haemonetics Corporation ... Italy, and Rest of Europe); Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)...

2019-09-08 - Feds Pave The Way To Expand Home Dialysis — But Patients Hit Roadblocks

(About 12% of Fresenius' 208,000 U.S. dialysis patients are on home therapies.) ... In a recent survey of caregivers providing complex care at home, 60% of ... In Canada, Australia and other countries where home dialysis is ...

2019-09-03 - Feds pave the way to expand home dialysis, but patients hit roadblocks | New Orleans' Multicultural News Source

(About 12 percent of Fresenius' 208,000 U.S. dialysis patients are on home therapies.) ... In a recent survey of caregivers providing complex care at home, ... In Canada, Australia and other countries where home dialysis is ...

2019-09-03 - Nephrology And Urology Devices Global Market Forecast To 2022

This industry includes establishments that produce dialysis devices ... Fresenius Medical Care AG & Co KGaA, Cook Group Incorporated, B.Braun Group, C. ... Countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.6M1320%N/A
#2
$23.3M146N/AN/A
#3
$35.1M15233%N/A
#4
$62.7M2596%N/A